Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

Suzanne L. Topalian, F. Stephen Hodi, Julie R. Brahmer, +27

New England Journal of Medicine

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

Julie R. Brahmer, Scott S. Tykodi, Laura Q.M. Chow, +23

New England Journal of Medicine

Type, Density, and Location of Immune Cells Within Human Colorectal Tumors Predict Clinical Outcome

Jérôme Galon, Anne Costes, Fátima Sánchez‐Cabo, +13

Science

Tumor ImmunologyCancer ImmunosurveillanceAdaptive Immune ResponseMedicineImmunology +10

Nivolumab plus Ipilimumab in Advanced Melanoma

Jedd D. Wolchok, Harriet M. Kluger, Margaret K. Callahan, +21

New England Journal of Medicine

Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma

Omid Hamid, Caroline Robert, Adil Daud, +23

New England Journal of Medicine

Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

Lin Zhang, José R. Conejo-García, Dionyssios Katsaros, +9

New England Journal of Medicine

Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria

Jedd D. Wolchok, Axel Hoos, Steven O’Day, +9

Clinical Cancer Research

Association of PD-1, PD-1 Ligands, and Other Features of the Tumor Immune Microenvironment with Response to Anti–PD-1 Therapy

Janis M. Taube, Alison Klein, Julie R. Brahmer, +7

Clinical Cancer Research

Survival, Durable Tumor Remission, and Long-Term Safety in Patients With Advanced Melanoma Receiving Nivolumab

Suzanne L. Topalian, Mario Sznol, David F. McDermott, +18

Journal of Clinical Oncology

Effector Memory T Cells, Early Metastasis, and Survival in Colorectal Cancer

Franck Pagès, Anne Berger, Matthieu Camus, +13

New England Journal of Medicine

Immune EvasionEarly MetastasisCancer ImmunosurveillanceImmunotherapyMedicine +12